Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
about
Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Oncogenic KRAS-associated gene ...... strategy in colorectal cancer.
@en
type
label
Oncogenic KRAS-associated gene ...... strategy in colorectal cancer.
@en
prefLabel
Oncogenic KRAS-associated gene ...... strategy in colorectal cancer.
@en
P2093
P2860
P356
P1433
P1476
Oncogenic KRAS-associated gene ...... strategy in colorectal cancer.
@en
P2093
S M J M Yatim
P2860
P2888
P304
P356
10.1038/ONC.2017.120
P407
P50
P577
2017-05-01T00:00:00Z
P6179
1085098354